# Who Could Benefit from Vumerity?
Keywords: Vumerity, RRMS, gastrointestinal symptoms, dimethyl fumarate, oral treatment, disease-modifying therapy, GI tolerability, multiple sclerosis, IBS, ARR, efficacy, tolerability, convenience

> This page provides information about Vumerity, a treatment option for relapsing-remitting multiple sclerosis (RRMS), focusing on its benefits for patients experiencing gastrointestinal (GI) side effects from other therapies, its efficacy, and its suitability for various patient profiles.

## Details
- [Introducing Sam](#sam): A 32-year-old personal trainer experiencing GI side effects from dimethyl fumarate, seeking a convenient oral treatment with minimal daily life impact.
- [Introducing Megan](#megan): A 28-year-old police officer newly diagnosed with RRMS, struggling with GI side effects and looking for a flexible long-term treatment option.
- [Introducing Sophie](#sophie): A 36-year-old accountant on injectable therapy with injection site reactions, seeking a more tolerable, convenient alternative mindful of her IBS.
- [How can Vumerity help support your eligible patients’ treatment needs?](#support): Highlights Vumerity’s improved GI tolerability, simple oral dosing, and established efficacy profile, making it a suitable option for eligible RRMS patients.
- [Wondering how to explain Vumerity to your patients?](#): Provides access to patient support tools for healthcare professionals to aid discussions about treatment options.